Expertise in
7
conditions

Dr. Paul B. Gilman

Hematology Oncology
100 Lancaster Ave, Main Line Oncology Hematology Associates, 
Wynnewood, PA 
Expertise in
7
conditions
100 Lancaster Ave, Main Line Oncology Hematology Associates, 
Wynnewood, PA 

Overview

Paul Gilman is a Hematologist Oncology provider practicing medicine in Wynnewood, Pennsylvania.

Dr. Gilman is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Bone Graft, and Vertebroplasty.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology Oncology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

100 Lancaster Ave, Main Line Oncology Hematology Associates, Wynnewood, PA 19096

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Enrollment Status: Terminated
Publish Date: February 20, 2026
Intervention Type: Drug, Biological
Study Drugs: Nivolumab, Cisplatin, Pemetrexed Disodium, Gemcitabine Hydrochloride
Study Phase: Phase 2
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
View 4 Less Clinical Trials

14 Total Publications

Prediction of Moderate to Severe Delayed Chemotherapy-Induced Nausea Using a Novel Algorithm Incorporating Individual Patient Factors.
Prediction of Moderate to Severe Delayed Chemotherapy-Induced Nausea Using a Novel Algorithm Incorporating Individual Patient Factors.
Journal: Cancer medicine
Published: November 04, 2025
Similar Doctors
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Referral may be required
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (6.4 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider practicing medicine in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Alveolar Soft Part Sarcoma, and Bone Tumor.

Expertise in
37
conditions
Dr. Henry C. Fung
Hematology Oncology | Transplant Surgery
Expertise in
37
conditions
Dr. Henry C. Fung
Hematology Oncology | Transplant Surgery
Referral may be required

Fox Chase Cancer Center

333 Cottman Avenue, 
Philadelphia, PA 
 (10.5 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Fung is a Hematologist Oncology specialist and a Transplant Surgeon practicing medicine in Philadelphia, Pennsylvania. Dr. Fung is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
40
conditions
Dr. Stephen J. Windsor
Hematology Oncology
Expertise in
40
conditions
Dr. Stephen J. Windsor
Hematology Oncology
Referral may be required

Riverview Medical Center

1 Riverview Plaza, Cancer Center, 
Red Bank, NJ 
 (9.3 miles away)
732-576-8610
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Windsor is a Hematologist Oncology provider practicing medicine in Red Bank, New Jersey. Dr. Windsor is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Paul B. Gilman

How do I make an appointment with Dr. Paul B. Gilman?

You can book an appointment with Dr. Paul B. Gilman by calling their office at 610-645-2494. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul B. Gilman a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul B. Gilman is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul B. Gilman specialize in?

While Dr. Paul B. Gilman is a Hematology Oncology, they have specific expertise in Angiosarcoma, Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Paul B. Gilman participate in research or clinical trials?

Yes. Dr. Paul B. Gilman has published 14 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Paul B. Gilman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul B. Gilman accept my insurance?

Dr. Paul B. Gilman accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 610-645-2494 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilman's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile